Cart is empty Danish drugmaker Novo Nordisk reported Thursday a sharp rise in third quarter sales and profits driven by the success of its anti-diabetes and anti-obesity treatments Ozempic and Wegovy.
Danish drugmaker Novo Nordisk reported Thursday a sharp rise in third quarter sales and profits driven by the success of its anti-diabetes and anti-obesity treatments Ozempic and Wegovy.
Leave A Comment